CLL

patient care perspectives

by Susan O’Brien, MD

Noncovalent BTK inhibitors (eg, pirtobrutinib) have generated promising data in the later-line treatment of chronic lymphocytic leukemia (CLL). Piv......READ MORE

expert roundtables

by Jennifer R. Brown, MD, PhD; John C. Byrd, MD; and Susan O’Brien, MD

Although active surveillance may cause anxiety among patients, the treatment of asymptomatic, early-stage chronic lymphocytic leukemia (CLL) is not......READ MORE

expert roundtables

by Jennifer R. Brown, MD, PhD; John C. Byrd, MD; and Susan O’Brien, MD

Trends in the frontline treatment of chronic lymphocytic leukemia (CLL) include the widespread use of Bruton tyrosine kinase (BTK) inhibitor therap......READ MORE

clinical topic updates

by Jennifer R. Brown, MD, PhD

Minimal residual disease (MRD) is a sensitive indicator of disease burden in chronic lymphocytic leukemia (CLL). While MRD analysis is becoming mor......READ MORE

patient care perspectives

by John C. Byrd, MD

Older patients with chronic lymphocytic leukemia (CLL) have more options for well-tolerated treatment than in the past. Planning treatment involves......READ MORE